Changes in susceptibility to posaconazole in clinical isolates of Candida albicans

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 1, 2004, Pages 74-80

  Li, Xin ^a   Brown, Nathaniel ^a   Chau, Andrew S ^a   López Ribot, José L ^b   Ruesga, Maria T ^c   Quindos, Guillermo ^c   Mendrick, Cara A ^a   Hare, Roberta S ^a   Loebenberg, David ^a   DiDomenico, Beth ^a   McNicholas, Paul M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Azoles; Drug resistance; Efflux pumps; ERG11

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; ITRACONAZOLE; LEUCINE; MULTIDRUG RESISTANCE PROTEIN 1; POSACONAZOLE; PROLINE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLELE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DRUG MONITORING; DRUG STRUCTURE; DRUG TARGETING; FUNGAL GENE; FUNGUS CULTURE; FUNGUS ISOLATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; GENETIC SELECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MISSENSE MUTATION; MOLECULAR TYPING; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; OROPHARYNX; PATHOGENESIS; POLYMERASE CHAIN REACTION; SACCHAROMYCES CEREVISIAE; STRUCTURE ACTIVITY RELATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTICS, ANTIFUNGAL; CANDIDA ALBICANS; CANDIDIASIS, ORAL; DRUG RESISTANCE, FUNGAL; GENES, VIRAL; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; TRIAZOLES;

EID: 9144274977     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh027     Document Type: Article

References (24)

1. Pfaller, M. A., Jones, R. N., Messer, S. A. et al. (1998). National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagnostic Microbiology and Infectious Disease 31, 327-32.
2. Vanden Bossche, H., Dromer, F., Improvisi, I. et al. (1998). Antifungal drug resistance in pathogenic fungi. Medical Mycology 36, 119-28.
3. Latgé, J.-P. (1999). Aspergillus fumigatus and aspergillosis. Clinical Microbiology Reviews 12, 310-50.
4. Ghannoum, M. A. & Rice, L. B. (1999). Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clinical Microbiology Reviews 12, 501-17.
5. Sanglard, D. & Odds, F. C. (2001). Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infectious Diseases 2, 73-85.
6. Perea, S., Lopez-Ribot, J. L., Kirkpatrick, W. R. et al. (2001). Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 45, 2676-84.
7. Kelly, S. L., Lamb, D. C. & Kelly, D. E. (1999). Y132H substitution in Candida albicans sterol 14α-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiology Letters 180, 171-5.
8. Lamb, D. C., Kelly, D. E., White, T. C. et al. (2000). The R467K amino acid substitution in Candida albicans sterol 14α-demethylase causes drug resistance through reduced affinity. Antimicrobial Agents and Chemotherapy 44, 63-7.
9. White, T. C. (1997). Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrobial Agents and Chemotherapy 41, 1482-7.
10. Kelly, S. L., Lamb, D. C., Kelly, D. E. et al. (1997). Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Letters 400, 80-2.
11. Geber, A., Hitchcock, C. A., Swartz, J. E. et al. (1995). Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrobial Agents and Chemotherapy 39, 2708-17.
12. Cacciapuoti, A., Loebenberg, D., Corcoran, E. et al. (2000). In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrobial Agents and Chemotherapy 44, 2017-22.
13. National Committee for Clinical Laboratory Standards. (1997). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A. NCCLS, Wayne, PA, USA.
14. Brieland, J., Essig, D., Jackson, C. et al. (2001). Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice. Infection and Immunity 69, 5046-55.
15. Pfaller, M. A., Messer, S. A., Hollis, R. J. et al. (2002). In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrobial Agents and Chemotherapy 46, 1723-7.
16. Pfaller, M. A., Messer, S. A., Hollis, R. J. et al. (2001). In vitro activities of posaconazole (SCH56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy 45, 2862-4.
17. Favre, B., Didmon, M. & Ryder, N. S. (1999). Multiple amino acid substitutions in lanosterol 14α-demethylase contribute to azole resistance in Candida albicans. Microbiology 145, 2715-25.
18. Marichal, P., Koymans, L., Willemsens, S. et al. (1999). Contribution of mutations in the cytochrome P450 14α-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145, 2701-13.
19. Sanglard, D., Ischer, F., Koymans, L. et al. (1998). Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrobial Agents and Chemotherapy 42, 241-53.
20. White, T. C. Holleman, S., Dy, F et al. (2002). Resistance mechanisms in clinical isolates of Candida albicans. Antimicrobial Agents and Chemotherapy 46, 1704-13.
21. Sanglard, D., Ischer, F. & Bille, J. (2002). Interactions of ravuconazole (RVZ) with yeast multidrug efflux transporters and different cytochrome P450 mutant forms. In 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract M-221, p. 379. American Society for Microbiology, Washington, DC, USA.
22. Manavathu, E. K., Cutright, J. L., Loebenberg, D. et al. (2000). A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). Journal of Antimicrobial Chemotherapy 46, 229-34.
23. Podust, L. M., Poulos, T. L. & Waterman, M. R. (2001). Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51 from Mycobacterium tuberculosis in complex with azole inhibitors. Proceedings of the National Academy of Sciences, USA 98, 3068-73.
24. Xiao, L., Madison, V., Chau, A. S. et al. (2004). Three-dimensional models of the wild-type and mutated forms of the cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into the binding of posaconazole. Antimicrobial Agents and Chemotherapy 48, in press.